Trial Profile
Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea Therapy in the Treatment of High Risk Polycythemia Vera (PV) and High Risk Essential Thrombocythemia (ET)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 14 Jan 2022
Price :
$35
*
At a glance
- Drugs Peginterferon alfa-2a (Primary) ; Aspirin; Hydroxycarbamide
- Indications Essential thrombocythaemia; Polycythaemia vera
- Focus Therapeutic Use
- Acronyms PEGHU-Phase3
- 10 Jan 2022 Primary endpoint (complete response (CR) rate) has not been met, according to Results published in the Blood.
- 10 Jan 2022 Results published in the Blood
- 08 Dec 2020 Results of pooled analysis (of data from MPN-RC 111 and MPN-RC 112 studies) assessing the Symptom burden and quality of life in high-risk essential Thrombocythemia and Polycythemia Vera patients presented at the 62nd Annual Meeting and Exposition of the American Society of Hematology